New 'Living Drug' trial offers hope for patients with aggressive blood cancers
Disease control
Recruiting now
This early-stage trial is testing the safety and best dose of a new type of personalized cell therapy called MB-CART19.1. It is for adults and children (ages 2-70) with certain B-cell blood cancers that have come back or have not responded to standard treatments. Doctors will col…
Phase: PHASE1 • Sponsor: Nelson Hamerschlak • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC